Principal ScientistAmpersand BiomedicinesBoston, Massachusetts, United States
Disclosure information not submitted.
Targeting IL-22 activity to the gut epithelium confers disease benefit without provoking skin inflammation
Saturday, April 18, 20261:33 PM - 1:45 PM US ET